Banque Pictet & Cie SA lifted its position in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 20.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 86,207 shares of the company's stock after purchasing an additional 14,792 shares during the quarter. Banque Pictet & Cie SA's holdings in QIAGEN were worth $3,415,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Beverly Hills Private Wealth LLC bought a new stake in QIAGEN during the 1st quarter worth about $299,000. Crossmark Global Holdings Inc. raised its position in shares of QIAGEN by 13.1% in the 1st quarter. Crossmark Global Holdings Inc. now owns 43,503 shares of the company's stock valued at $1,747,000 after acquiring an additional 5,034 shares during the period. Envestnet Asset Management Inc. acquired a new stake in shares of QIAGEN in the 1st quarter valued at approximately $13,463,000. Allspring Global Investments Holdings LLC raised its position in shares of QIAGEN by 4.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,445,641 shares of the company's stock valued at $96,605,000 after acquiring an additional 109,481 shares during the period. Finally, Blue Trust Inc. raised its position in shares of QIAGEN by 30.5% in the 1st quarter. Blue Trust Inc. now owns 13,519 shares of the company's stock valued at $543,000 after acquiring an additional 3,157 shares during the period. Institutional investors own 70.00% of the company's stock.
QIAGEN Price Performance
QGEN stock traded down $0.42 during midday trading on Friday, reaching $48.13. The company had a trading volume of 2,421,661 shares, compared to its average volume of 1,215,596. The company has a market capitalization of $10.70 billion, a price-to-earnings ratio of 120.67, a price-to-earnings-growth ratio of 2.45 and a beta of 0.68. The stock has a 50 day moving average price of $45.37 and a 200-day moving average price of $42.81. QIAGEN N.V. has a 1-year low of $37.63 and a 1-year high of $49.30. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.37 and a quick ratio of 2.83.
QIAGEN (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. The business had revenue of $483.46 million during the quarter, compared to the consensus estimate of $465.66 million. QIAGEN had a return on equity of 14.61% and a net margin of 4.68%. QIAGEN's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.44 earnings per share. Equities research analysts expect that QIAGEN N.V. will post 2.26 earnings per share for the current year.
QIAGEN Dividend Announcement
The firm also recently announced a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were paid a dividend of $0.25 per share. This represents a yield of 0.52%. The ex-dividend date of this dividend was Wednesday, July 2nd. QIAGEN's payout ratio is 62.50%.
Analysts Set New Price Targets
Several analysts have commented on QGEN shares. Barclays initiated coverage on shares of QIAGEN in a report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price on the stock. Robert W. Baird lifted their price objective on shares of QIAGEN from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Redburn Atlantic cut shares of QIAGEN from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Wall Street Zen raised shares of QIAGEN from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 15th. Finally, Bank of America boosted their target price on shares of QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. Seven research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, QIAGEN currently has a consensus rating of "Hold" and an average target price of $49.40.
Get Our Latest Research Report on QIAGEN
QIAGEN Company Profile
(
Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
Further Reading
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
